Sensus Healthcare, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SRTS research report →
Range $4 – $5.5
Price Chart
About the company
Sensus Healthcare, Inc. operates as a medical technology enterprise, manufacturing and distributing radiation therapy apparatuses to medical institutions across the globe. The company's portfolio leverages superficial radiation therapy (SRT), a cutting-edge low-energy X-ray methodology.
- CEO
- Joseph C. Sardano
- IPO
- 2016
- Employees
- 60
- HQ
- Boca Raton, FL, US
Get TickerSpark's AI analysis on SRTS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $37.20M
- P/E
- -2.38
- Fwd P/E
- 3.32
- PEG
- 0.02
- P/S
- 2.29
- P/B
- 1.07
- EV/EBITDA
- -2.24
- Div Yield
- 0.00%
- Gross Margin
- 41.80%
- Op Margin
- -74.05%
- Net Margin
- -96.49%
- ROE
- -38.65%
- ROIC
- -34.45%
Latest fiscal year · YoY change
- Revenue
- $27.48M-34.3%
- Gross Profit
- $11.87M-51.4%
- Op Income
- $-10,307,000
- Net Income
- $-7,719,000-216.1%
- EPS
- $-0.47-214.6%
- OCF Growth
- +163.5%
- FCF Growth
- +130.0%
- 52W High
- $5.49
- 52W Low
- $2.14
- 50D MA
- $2.89
- 200D MA
- $3.37
- Beta
- 1.19
- RSI (14)
- 36
- Avg Volume
- 208.74K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Sensus said Q3 showed improving mix and margins, with more direct dermatology demand, while management leaned on CPT-code-driven adoption and new recurring revenue opportunities.· November 12, 2026
- Revenue was $6 million, down 13% from $6.9 million a year ago, but gross margin improved to about 55% from 39%.
- The company shipped 26 systems versus 16 last year; excluding 8 delayed carryover units, it shipped 18 systems in Q3.
- Management said it delivered more units directly to dermatology practices in Q3 than in the prior two quarters combined.
- Two private-equity-backed dermatology groups became new customers, with one buying outright and one using a Fair Deal Agreement.
- The company highlighted its 1,000th SRT system placement and growing interest in Sensus Link and other recurring-revenue programs.
Q3 revenue was $6 million, down 13% from $6.9 million in Q3 2025. Gross profit was $3.3 million versus $2.7 million last year, and gross margin improved to approximately 55% from 39%. Adjusted EBITDA was negative $1.5 million versus negative $2.4 million a year ago; net loss was $1.5 million, or $0.09 per share, versus a net loss of $0.9 million, or $0.06 per share last year, though Q3 2025 included an income tax benefit of approximately $1.5 million. Cash, restricted cash and cash equivalents were $12.9 million at quarter end, and the company had no outstanding borrowings on its revolving line of credit. The company did not provide formal next-quarter or full-year financial guidance, but said it expects to build on Q3 momentum in Q4 and continues focusing on converting opportunities into revenue and sustainable profitability.
Joe Sardano framed the quarter as evidence that Sensus is moving from educating the market about reimbursement to converting interest into adoption. He emphasized the company’s five priorities, the new CPT-code reimbursement environment, broader customer reach beyond single practices, and a strategy that combines equipment sales with recurring revenue from software, services and utilization-based programs. His tone was confident and strategic, repeatedly stressing that the company is building a more diversified and predictable business.
Javier Rampolla focused on the financial drivers behind the quarter, especially mix and customer composition. He said revenue declined because of more lower-priced SRT-100 systems versus Vision systems and because there were no sales to the historically largest customer, while gross margin expanded to about 55% from 39% due mainly to product mix. He also cited higher G&A from legal and professional fees, flat selling and marketing, lower R&D from reduced lobbying costs and headcount, and a cash balance of $12.9 million with no revolver borrowings.
Analysts focused on the proposed 26% increase in hospital-based SRT delivery codes, the Australia opportunity, the mix shift toward SRT-100 versus Vision, the role of private-equity-backed practices, and adoption of Sensus Link. Management said the 26% hospital-code increase is proposed by CMS and expects it to take effect on January 1, 2027, adding that the move applies to Level 1 radiation treatment delivery in hospital coding. On Australia, management said SRT is already cleared there and that the market is underpenetrated; on private equity groups, one bought outright and one chose Fair Deal, showing the flexibility of the model. They also said Sensus Link adoption is growing monthly.
The call pointed to improving demand quality: more direct sales to dermatology practices, a broader pipeline, and initial wins with two large private-equity-backed groups that could expand across roughly 450 practices. Management believes the new reimbursement framework is making SRT easier to sell, and it sees room for margin improvement as mix shifts toward SRT-100 and recurring revenue builds.
Revenue still declined year over year, and the company did not give formal guidance, so the pace of conversion remains uncertain. Management also noted that larger group discussions can take longer than single-practice sales, and some revenue is delayed because Fair Deal and rental arrangements are recognized over time rather than at shipment. Cash declined to $12.9 million from $15.2 million in June, and profitability remained negative despite better margins.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 81.3%
- Shares Outstanding
- 16.46M
- Float Shares
- 13.39M
of shares held by institutions
41 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Pacific Ridge Capital Partners, LLC | 784.34K | ▼ 5.34K |
| Vanguard Group Inc | 728.92K | 0 |
| Vanguard Capital Management LLC | 660.40K | 0 |
| Dimensional Fund Advisors LP | 301.07K | ▼ 15.05K |
| Divisadero Street Capital Management, LP | 278.49K | 0 |
| Renaissance Technologies LLC | 229.63K | ▼ 12.70K |
| Geode Capital Management, LLC | 154.15K | 0 |
| Sachetta, LLC | 152.01K | ▲ 1.50K |
| Greenline Wealth Management LLC | 148.77K | ▲ 20.00K |
| Ubs Group AG | 143.15K | ▼ 9.43K |
| North Star Investment Management Corp. | 125.59K | 0 |
| Perritt Capital Management Inc | 125.59K | 0 |
Held by 34 ETFs
Biggest fund positions in SRTS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 18, 26 | Cornish Megan | buy | 2,200 |
| Nov 17, 26 | Sachetta Eric | buy | 81,575 |
| Nov 16, 26 | Sardano Joseph C | buy | 30,000 |
| Aug 31, 26 | Sachetta Eric | buy | 27,304 |
| Aug 28, 26 | Sachetta Eric | buy | 37,537 |
| Aug 27, 26 | Sachetta Eric | buy | 10,925 |
| Aug 26, 26 | Sachetta Eric | buy | 9,708 |
| Aug 24, 26 | Sachetta Eric | buy | 34,697 |
| Aug 20, 26 | Sardano Joseph C | buy | 20,000 |
| Aug 21, 26 | Sachetta Eric | buy | 7,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SRTS coverage
Recent articles, reports, and earnings notes.
No research on SRTS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SRTS report →What Sensus Healthcare (SRTS) Said on Its Q3 Earnings Call
marketbeat.com · Nov 12
Sensus Healthcare, Inc. (SRTS) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 12
Sensus Healthcare Reports Third Quarter 2026 Financial Results and Business Highlights
businesswire.com · Nov 12
Sensus Healthcare Announces Sale of 1,000th SRT System, Marking Significant Commercial Milestone
businesswire.com · Nov 10
Reviewing UFP Technologies (NASDAQ:UFPT) & Sensus Healthcare (NASDAQ:SRTS)
defenseworld.net · Oct 22
Sensus Healthcare, Inc. (NASDAQ:SRTS) Stock Has Consensus Price Target of $5.83 According to Analysts
defenseworld.net · Oct 16
Contrasting Sensus Healthcare (NASDAQ:SRTS) and STAAR Surgical (NASDAQ:STAA)
defenseworld.net · Sep 29
Sensus Healthcare Q2 Earnings Call Highlights
marketbeat.com · Aug 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.